NewsBenzinga펩젠, PGN-EDODM1의 2상 FREEDOM2-DM1 연구 데이터 발표···평균 스플라이싱 교정률 46.5% 및 높은 내약성 확인 펩젠, PGN-EDODM1의 2상 FREEDOM2-DM1 연구 데이터 발표···평균 스플라이싱 교정률 46.5% 및 높은 내약성 확인 Benzinga 2026.11.10 12:07 (GMT+0) Open on Benzinga Other news AI models can be tricked into identifying civilians as military targets by telling them it’s a game Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT